Haematopoietic stem cell transplantation in Switzerland: Report from the Swiss Transplant Working Group for Blood and Marrow Transplantation (STABMT) Registry 1997-2003

Swiss Medical Weekly

Volumn 136, Issue 3-4, 2006, Pages 50-58

  Passweg, J ^b   Baldomero, H ^a   Chapuis, B ^b   Leibundgut, K ^c   Schanz, U ^d   Gratwohl, A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Haematopoietic stem cell transplantation; Outcome; Switzerland

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHILD; CONTROLLED STUDY; DONOR; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; REGISTER; RELAPSE; SOLID TUMOR; SURVIVAL RATE; SWITZERLAND; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 33144472496     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Thomas ED. Bone marrow transplantation: a review. Semin Hematol 1999;36:95-103.
2. Horowitz M. Uses and Growth of Hematopoietic Cell Transplantation. In: Blume KG, Forman SJ, Appelbaum FR (ed). Thomas' Hematopoietic cell transplantation. Blackwell Scientific Publishers Inc., London, New York, 2004; pp 9-15.
3. Craddock C. Haemopoietic stem-cell transplantation: recent progress and future promise. Lancet Oncol 2000;1:227-34.
4. Urbano-Ispizua A, Schmitz N, de Witte T, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2002;29:639-46.
5. Gratwohl A, Baldomero H, Horisberger B, et al. Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002;100:2374-86.
6. Baron F, Storb R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol 2004;26:71-94.
7. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174-8.
8. Cohen Y, Nagler A. Umbilical cord blood transplantation - how, when and for whom? Blood Rev 2004;18:167-79.
9. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation-how much of the promise has been realized? Nat Med 2005;11:605-13.
10. Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature Review 2005;435:620-7.
11. Gratwohl A, Passweg J, Bocelli-Tyndall C, Fassas A, van Laar JM, Farge D, et al. Autoimmune Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2005;35: 869-79.
12. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175-81.
13. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard risk leukemia. Blood 2002;100:761-7.
14. Rubinstein A, Speck B, Jeannet M. Successful bone-marrow transplantation in a lymphopenic immunologic deficiency syndrome. N Engl J Med 1971;285:1399-402.
15. Imbach P, Odavic R, Bleher EA, Bucher U, Deubelbeiss KA, Wagner HP. Autologous bone marrow reimplantation in children with advanced tumor. Schweiz Med Wochenschr 1979; 109:283-7.
16. Gratwohl A, Gmur J, Chapuis B, Baumgartner C, Wursch A, Lori A, et al. 12 years' experience in bone marrow transplantation in leukemic patients in Switzerland. Schweiz Med Wochenschr l986;116:1477-8.
17. Passweg JR, Gratwohl A, Tichelli A, Hoffmann T, Nissen C, Kuhne T, et al. 25 years allogenic bone marrow transplantation in Basel: 1973-1998. Schweiz Med Wochenschr 1998;128: 1568-74.
18. Brun del Re GP, Tschopp L, Cerny T, Bucher U. Autologous bone marrow transfusion in the treatement of adults with hematologic neoplasms. Experiences from Berne. Schweiz Med Wochenschr 1898;119:902-10.
19. Leibundgut K, Hirt A, Luthy AR, Wagner HP, Tobler A. Single institution experience with mobilization, harvesting and reinfusion of peripheral blood stem cells in children with a solid tumor or leukemia. Pediatr Hematol Oncol 1994;11:215-21.
20. Chapuis B, Helg C, Maurice P, Aapro M, Jeannet M, Irle C, Montandon N, Kaestli M, Wyss M, Wacker P. super intensive treatment followed by bnone marrow autograft in cases of hematologic neoplasms and solid tumors. Schweiz Med Wochenschr 1988;118:341-6.
21. Gmur J, Burger W, Frick P. Low early mortality after allogeneic bone marrow transplantation thanks to rigorous sterility measures, modified whole body irradiation, cyclosporin A and antiviral precautions. Schweiz Med Wochenschr 1985;115:1524-5.
22. Regazzoni S, Marini G, Grob A, Pedrazzini A, Goldhirsch A, Castelli D, et al. High-dose chemotherapy with autologous stem cell transplantation is feasible and safe in a regional hospital. A 6-year experience in southern Switzerland. Bone Marrow Transplant 1997;19:3-7.
23. Schmitz N, Gratwohl A, Goldman JM. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1996 and proposals for an operational classification. Bone Marrow Transplant 1996;17:471-7.
24. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous haematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000;342:1069-76.
25. Elfenbein GJ. Stem-cell transplantation for high-risk breast cancer. N Engl J Med 2003 349:80-2.
26. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with haematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003;349:7-16.
27. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001;344:1031-7.
28. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N Engl J Med 2003; 348:994-1004.
29. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1985;332:217-23.
30. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
31. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome. N Engl J Med 1996;335:91-7.
32. Gratwohl A, Baldomero H, Labar B, et al. Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Evolution of hematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey. Croat Med J 2004;45:689-94.
33. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 87-92.
34. Slavin S. Smarter rather than stronger treatment of haematological malignancies and non-malignant indications for stem-cell transplantation. Lancet 2004;22-124.
35. Haddad N, Rowe JM. Current indications for reduced-intensity allogeneic stem cell transplantation. Best Pract Res Clin Haematol 2004;17:377-86.
36. Link H, Schmitz N, Gratwohl A, Goldman JM. Standards for specialist units undertaking blood and marrow stem cell transplants - recommendations from the EBMT. Bone Marrow Transplant 1995;16:733-63.
37. Kvalheim G, Urbano-Ispizua A, Gratwohl A. Regulatory aspects and accreditation of the clinical use of hematopoietic progenitor cells in Europe. J Biol Regul Homeost Agents 2001; 5:79-80.